A personalized surveillance strategy according to risk stratification appears to be safe in the management of patients with serrated polyposis syndrome, reducing colonoscopy burden without risking an increased colorectal cancer incidence, a recent study has shown.
Use of tioguanine for at least 12 months appears to be effective in the maintenance treatment of inflammatory bowel disease (IBD), and while adverse events are common, most are clinically tolerable, according to a recent study.
Cognitive behavioural therapy (CBT), delivered over the web or phone, yields superior improvements in irritable bowel syndrome (IBS) symptoms and more favourable effects on life and mood in comparison with treatment as usual, according to data from the ACTIB* trial.
Ustekinumab, delivered subcutaneously, is effective for patients with inflammatory bowel disease (IBD) receiving concomitant treatment for dermatological or rheumatological conditions, a recent study has found.
Hepatocellular carcinoma (HCC) patients receiving sorafenib may have poor survival if they present with pretreatment elevated platelets or have advanced Barcelona Clinic Liver Cancer (BCLC) stage, a recent study has shown.
Individuals with type 2 diabetes mellitus (T2D) may be at risk of developing gastric cancer even after receiving Helicobacter pylori (H. pylori) eradication therapy, demonstrated a study from Hong Kong.
New drug application approved by US FDA as of 01 - 15 September 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.